Gordon Tomaselli Daniel Jones REFERENCE: Late Breaking Clinical Trials 1, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida GORDON TOMASELLI, Johns Hopkins Universit
Gordon Tomaselli
Daniel Jones
REFERENCE: Late Breaking Clinical Trials 1, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, FloridaGORDON TOMASELLI, Johns Hopkins University, BaltimoreCOMMENT: DANIEL JONES, President, American Heart Association, University of Mississippi, JacksonA potential new option for patients with acute coronary syndromes receiving coronary intervention has emerged following a report on the comparison of prasugrel, a new anti-platelet agent, with clopidogrel. Elliott Antman from Brigham and Women’s Hospital in Boston gave the American Heart Association his findings and recommendations about when and in which patients prasugrel might be favored.Gordon Tomasellidiscussed the findings with Sarah Maxwell.
Tags
Related Episodes
LDL-How Low?
Terje Pedersen Terje Pedersen, Ulleval University, Oslo Eugene Braunwald, Harvard University, Boston Lowering LDL Cholesterol intensively as a means of treating aortic stenosis was found to have no be
Audio Journal of Oncology Volume 16 Number 11
Scientific Editors: George Canellos (Boston), Pat Price (Manchester), Gianni Bonadonna (Milan), Gordon McVie (Milan) Sarah Maxwell and Peter Goodwin report from: American Society of Clinical Oncology
Audio Journal of Medicine
In this edition: 1. Training In Depression And Suicide: Need For Change? Stan Kutcher, Dalhousie University, Nova Scotia 2. Suicide Paradox Explained: Australian National Strategy Barry Nurcombe, Prin